BRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming by Sevinç, K, Sevinç, GG, Cavga, AD, Philpott, M, Kelekçi, S, Can, H, Cribbs, AP, Yıldız, AB, Yılmaz, A, Ayar, ES, Arabacı, DH, Dunford, JE, Ata, D, Sigua, LH, Qi, J, Oppermann, U, Onder, TT

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities by Yedier-Bayram, O, Gokbayrak, B, Kayabolen, A, Aksu, AC, Cavga, AD, Cingöz, A, Kala, EY, Karabiyik, G, Günsay, R, Esin, B, Morova, T, Uyulur, F, Syed, H, Philpott, M, Cribbs, AP, Kung, SHY, Lack, NA, Onder, TT, Bagci-Onder, T

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival by Ozyerli-Goknar, E, Kala, EY, Aksu, AC, Bulut, I, Cingöz, A, Nizamuddin, S, Biniossek, M, Seker-Polat, F, Morova, T, Aztekin, C, Kung, SHY, Syed, H, Tuncbag, N, Gönen, M, Philpott, M, Cribbs, AP, Acilan, C, Lack, NA, Onder, TT, Timmers, HTM, Bagci-Onder, T